These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 19874801

  • 1. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
    Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.
    Biochem Pharmacol; 2010 Mar 01; 79(5):688-97. PubMed ID: 19874801
    [Abstract] [Full Text] [Related]

  • 2. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
    Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S.
    Blood; 2008 Aug 01; 112(3):793-804. PubMed ID: 18505786
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Blood; 2008 Apr 15; 111(8):4355-64. PubMed ID: 18268096
    [Abstract] [Full Text] [Related]

  • 4. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
    Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY.
    Carcinogenesis; 2012 Feb 15; 33(2):285-93. PubMed ID: 22116466
    [Abstract] [Full Text] [Related]

  • 5. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
    Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS.
    J Cell Mol Med; 2011 Oct 15; 15(10):2057-70. PubMed ID: 21091633
    [Abstract] [Full Text] [Related]

  • 6. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 15; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 15; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 10. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH.
    PLoS One; 2011 Apr 26; 6(4):e19164. PubMed ID: 21541334
    [Abstract] [Full Text] [Related]

  • 11. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 26; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 12. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
    Akahane D, Tauchi T, Okabe S, Nunoda K, Ohyashiki K.
    Cancer Sci; 2008 Jun 26; 99(6):1251-7. PubMed ID: 18429956
    [Abstract] [Full Text] [Related]

  • 13. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 14. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
    Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J.
    Cancer Res; 2006 Jan 15; 66(2):1007-14. PubMed ID: 16424036
    [Abstract] [Full Text] [Related]

  • 15. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J.
    Mol Cancer; 2010 May 19; 9():112. PubMed ID: 20482842
    [Abstract] [Full Text] [Related]

  • 16. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S, Holtz M, Gupta M, Bhatia R.
    Blood; 2004 Apr 15; 103(8):3167-74. PubMed ID: 15070699
    [Abstract] [Full Text] [Related]

  • 17. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.
    Oncotarget; 2012 Dec 15; 3(12):1557-65. PubMed ID: 23238683
    [Abstract] [Full Text] [Related]

  • 18. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.
    J Natl Cancer Inst; 2008 Jul 02; 100(13):926-39. PubMed ID: 18577747
    [Abstract] [Full Text] [Related]

  • 19. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
    Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O.
    Int J Oncol; 2013 Feb 02; 42(2):419-28. PubMed ID: 23233201
    [Abstract] [Full Text] [Related]

  • 20. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.